TD Cowen analyst Ritu Baral raised the firm’s price target on Madrigal Pharmaceuticals to $390 from $349 and keeps an Outperform rating on the shares. The firm noted the FDA approved THR-beta agonist Rezdiffra (resmetirom) for NASH with moderate to advanced fibrosis with no biopsy requirement in indication language.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals’ Rezdiffra™ Wins Accelerated FDA Approval
- Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
- Madrigal Pharmaceuticals price target raised to $405 from $275 at H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $338 from $336 at Canaccord
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
